SCHEMBL14048593

SCHEMBL14048593

CNCCC1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25183700 1.00
SCHEMBL10087663 0.94 CYP2D6 (0.41)
SCHEMBL21538638 0.84
SCHEMBL15743624 0.84
SCHEMBL19648470 0.83 CHRNB4 (0.33)
SCHEMBL2917254 0.79 GNAI3 (0.31)
SCHEMBL17460677 0.79 CYP2D6 (0.36)
SCHEMBL19112768 0.79 SAT1 (0.34)
SCHEMBL24017137 0.79 SIGMAR1 (0.55)
SCHEMBL13961615 0.78 CYP2D6 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111511730-B Amide substituted indole compounds useful as TLR inhibitors 百时美施贵宝公司 2023-07-25 CN claimed
CN-111511730-A Amide substituted indole compounds useful as T L R inhibitors 百时美施贵宝公司 2020-08-07 CN claimed
CN-111511730-B Amide substituted indole compounds useful as TLR inhibitors 百时美施贵宝公司 2023-07-25 CN disclosed
WO-2023086438-A1 PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
WO-2023086438-A1 PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
WO-2023086432-A1 PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
US-20220002151-A1 METHOD FOR PRODUCING COMPRESSED HYDROGEN USING ELECTROCHEMICAL SYSTEMS SAUDI ARABIAN OIL COMPANY (SA) 2022-01-06 US disclosed
CN-111511730-A Amide substituted indole compounds useful as T L R inhibitors 百时美施贵宝公司 2020-08-07 CN disclosed
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-08-10 US disclosed
US-20160185780-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-06-30 US disclosed
US-9242976-B2 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-01-26 US disclosed
CN-1665807-B Physiologically active substance MICROBIOPHARM JAPAN CO LTD 2013-09-11 CN disclosed
WO-2013025628-A1 JANUS KINASE INHIBITOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-02-21 WO disclosed
CN-1351498-B Pyrrolotriazines inhibitors of kinases BRISTOL MYERS SQUIBB CO 2012-08-15 CN disclosed
CN-101730693-A Process for producing macrolide compound and production intermediate thereof EISAI R&D MAN CO LTD 2010-06-09 CN disclosed
CN-1671856-B Novel physiologically active substances EISAI R&D MAN CO LTD 2010-05-12 CN disclosed
CN-101663296-A 12-membered ring macrolactam derivatives EISAI R&D MAN CO LTD 2010-03-03 CN disclosed
EP-1632483-B1 HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS AVENTIS PHARMA INC (US) 2008-10-29 EP disclosed
CN-1671856-A Novel physiologically active substances MERCIAN CORP (JP) 2005-09-21 CN disclosed
CN-1665807-A Novel physiolgically active substances MERCIAN CORP (JP) 2005-09-07 CN disclosed